Results 91 to 100 of about 30,845,260 (288)

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

Effectiveness, safety, and treatment patterns of GLP-1 receptor agonists in adolescents with obesity: a multicenter retrospective study from Saudi Arabia

Frontiers in Nutrition
BackgroundReal-world evidence on the use of glucagon-like peptide-1 (GLP-1) receptor agonists in pediatric obesity remains limited, particularly regarding treatment outcomes, safety, and clinical practice patterns.ObjectiveTo evaluate changes in body ...
Farah Kalagi, Lara Hamed, Sadeem Alrubaian, Fatimah Almuzain, Nisreen Alturkestany, Sulaiman Bah, Yasmin Algindan   +6 more
doaj   +1 more source

Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro‐Eating Disorder Community on X (Formerly Twitter)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are complex conditions with medical and psychosocial implications. Social media (SM) exposure has been associated with increased body image concerns and maladaptive eating behaviors. Pro‐eating disorder (pro‐ED) communities exist across SM platforms and often perpetuate ED‐related identities and behaviors.
Daisy Sun, Tovah Yanover, Helena Katona, Jennifer Couturier   +3 more
wiley   +1 more source

For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?

Biology
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have revolutionized the management of not only type 2 diabetes but also obesity. However, even with rapid therapeutic advances in GLP-1RAs, questions regarding the fundamental principles of GLP-1 ...
Charlise Giang, Jieyi Meng, Mahmoud Ali Mohammad, Zhenqi Liu, Xinle Wu, Yi Zhu   +5 more
doaj   +1 more source

GLP-1 Receptor Agonists In Diabetes And Weight Management

GLP-1 receptor agonists are highly effective in lowering blood sugar levels in type 2 diabetes without causing hypoglycemia and have demonstrated cardiovascular benefits, particularly for patients with ASCVD.
Tran, Nguyen An Khe
core  

Feasibility, Acceptability and Outcomes of Group CBT‐T: A Naturalistic Mixed‐Methods Comparison With Individual CBT‐T

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility of implementing 10‐session group cognitive behavioural therapy (CBT‐Tg) in routine outpatient eating disorder care and to descriptively examine outcomes of CBT‐Tg and individual CBT‐T (CBT‐Ti). Method Using a naturalistic, non‐randomised, mixed‐methods design, this implementation study was
Laura Dixon, Anastasia Harris, Victoria Taylor, Lily Spoozak, Sara Bartel, Susan Gamberg, Nami Trappenberg, Colby Price, Navjot Sandila, Elena Koning, Sarrah I. Ali, Erin Piercy, Glenn Waller, Aaron Keshen   +13 more
wiley   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

The Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao, Elise Chia-Hui Tan, PhD, Lin-Chieh Meng, MS, Yi-Chin Lin, PharmD MS, Ho-Min Chen, MS, Shang-Ting Guan, PharmD, ProfMD PhD Der-Cherng Tarng, PharmD, ProfMD PhD Chih-Yuan Wang, PharmD, Prof Liang-Kung Chen, PharmD   +8 more
doaj   +1 more source

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli [PDF]

Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Klein M, Cheney C, Hunter K
core  

Mechanisms of an Inhibitory Control Training to Reduce Binge Eating—The Randomized Controlled MIND BINGES Trial

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Psychotherapy is the first‐line treatment for eating disorders (EDs), yet only about half of patients benefit long‐term. Bulimia nervosa (BN), Binge‐Eating‐Disorder (BED), and non‐underweight EDs with regular binge eating (> 2 binge‐eating episodes per month within the last 3 months) (OSFED/UFED) form a transdiagnostic group ...
Sebastian M. Max, Katrin E. Giel, Christian Plewnia, Simone Weller, Andreas J. Fallgatter, Veronika Lossa, Stephan Zipfel, Kathrin Schag   +7 more
wiley   +1 more source

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Journal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette, Erin E. Mulvihill, Erin E. Mulvihill   +2 more
doaj   +1 more source